statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data...

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

Latest Ratings for OCUL
 DateFirmActionFromTo Mar 2022JMP SecuritiesMaintainsMarket Outperform Nov 2021JMP SecuritiesMaintainsMarket Outperform Oct 2021HC Wainwright & Co.MaintainsBuy
 View More...

The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Ocular Therapeutix (OCUL Research Report), with a pr...

Buy Rating Affirmed: Paxtrava's Promising Efficacy and Safety Profile in Glaucoma Treatment

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report)'s stock price rose 5.3% on Thursday . The stock traded as high as $8.92 and last traded at $8.90. Approximately 89,801 shares were traded...

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 5.3%

Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p&lt;0.0001) through six months, with clinically meaningful reductions of 24-30...

Ocular Therapeutix  Announces Positive Phase 2 PAXTRAVA  Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report)'s stock price fell 4% during trading on Monday . The company traded as low as $8.65 and last traded at $8.74. 176,569 shares changed hands...

Ocular Therapeutix (NASDAQ:OCUL)  Shares Down 4%

This is a signal that OCUL's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Ocular Therapeutix (OCUL, $9.3) Stochastic Oscillator left the oversold zone on March 27, 2024

BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, Ocular , the Company ), a biopharmaceutical company committed to enhancing people's vision and quality of...

Ocular Therapeutix  To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL  Get Free Report) have received a consensus recommendation of Buy from the five analysts that are currently covering the stock...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of "Buy" by Analysts

Ocular Therapeutix (NASDAQ:OCUL  Get Free Report) was upgraded by analysts at StockNews.com from a sell rating to a hold rating in a note issued to investors on...

Ocular Therapeutix (NASDAQ:OCUL) Raised to "Hold" at StockNews.com

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Volume	165.00
52-Wk High	$11.31
52-Wk Low	$2.00

OCUL Ocular Therapeutix Inc

About

Feed

News

Sentiment

Earnings

Fundamentals